Nanoparticle albumin-bound paclitaxel – first step of nanotechnology into clinical practice
Paclitaxel is an effective antitumor agent used for treatment of breast cancer, lung, stomach and pancreas. However, its own adverse effects and the use of toxic Cremophor EL as the solvent limit the application range of this drug. Associated with the albumin-bound nanoparticle paclitaxel (paclitaxe...
Saved in:
| Main Authors: | R. N. Alyautdin, B. K. Romanov, В. К. Лепахин, N. D. Bunyatyan, V. A. Merkulov, A. N. Mironov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Ministry of Health of the Russian Federation, Federal State Budgetary Institution «Scientific Centre for Expert Evaluation of Medicinal Products»
2022-06-01
|
| Series: | Безопасность и риск фармакотерапии |
| Subjects: | |
| Online Access: | https://www.risksafety.ru/jour/article/view/300 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Efficacy of albumin-bound paclitaxel versus paclitaxel in esophageal cancer: a systematic review and meta-analysis
by: Jiayang Song, et al.
Published: (2025-08-01) -
Effects of albumin-bound paclitaxel combined with Sophora subprostrate polysaccharide on inflammatory factors and immune function in breast cancer rats
by: Changli Ding, et al.
Published: (2025-05-01) -
Efficacy and safety of nanoparticle albumin-bound paclitaxel plus cisplatin or nedaplatin plus tegafur/gimeracil/oteracil as induction chemotherapy regimen for hypopharyngeal cancer
by: Cailing Jiang, et al.
Published: (2025-02-01) -
The Efficacy and Safety of Albumin‐Bound Paclitaxel Combined With Anlotinib and PD‐1/L1 Inhibitors For Treating Patients With Extensive‐Stage Small Cell Lung Cancer and Brain Metastasis: A Retrospective Cohort Study
by: Xiaobing Li, et al.
Published: (2024-12-01) -
Effect of liposome binding antisense oligonucleotide BP1003 on albumin-bound paclitaxel sensitivity in pancreatic cancer cells by inhibiting STAT3
by: FU Hua, ZHOU Guochao, CAI Rongmin, SONG Xin, YANG Dinghua
Published: (2025-05-01)